Equity Research on Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. - Strong Quarter for Dia

Equity Research on Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. - Strong Quarter for Diagnostic Substances

ID: 172695

(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 08/08/12 -- has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Diagnostic Substances industry and are offering free analytical research on (NASDAQ: RPTP) and (NASDAQ: IDXX). Register with us now to have free access to these research reports. Simply click on the link below.



Strong competition, costly drug trials and unfavorable currency exchanges are making it difficult for companies within the diagnostic substances industry to widen margins but not impossible. Get your free reports on and at . There is no commitment to join.

ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.



IDEXX Laboratory Corp. provides a good example of the adverse effects of macroeconomic headwinds. The company saw revenues dented by unfavorable currency rates in the last quarter but still managed to see organic revenue growth of 7% which is encouraging moving forward. report is accessible for free by registering today at



Maintaining a steady pipeline of drugs to market is perhaps as important as ever considering the current high levels of competition. This is especially so for treatments of rare diseases with small patient bases. The nephropathiccystinosis market illustrates this point. Currently, Mylan's Cystagon is the only available treatment but Raptor Pharmaceutical Corp.'s RP103 continues to make progress in its bid for approval. It could see approval as early as January of next year and significantly alter the current market. report is accessible for free by registering today at







The two stocks research reports are available for free by signing up now on the link below.





Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our visit this link .






Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Equity Research on Newmont Mining Corp. and Kinross Gold Corp. - Gold Companies Struggling With Costs Equity Research on Archer-Daniels-Midland Co. and Bunge Ltd. - Farm Products Suffering at the Hands of Adverse Weather Conditions
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 08.08.2012 - 12:15 Uhr
Sprache: Deutsch
News-ID 172695
Anzahl Zeichen: 2787

contact information:
Town:

NEW YORK, NY



Kategorie:

Investment Opinion



Diese Pressemitteilung wurde bisher 201 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Equity Research on Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. - Strong Quarter for Diagnostic Substances"
steht unter der journalistisch-redaktionellen Verantwortung von

Shinesrooms.com (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Shinesrooms.com



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z